Cleo Diagnostics (ASX:COV) FCF Yield % : -7.87 (As of May. 11, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cleo Diagnostics's Trailing 12-Month Free Cash Flow is A$-1.77 Mil, and Market Cap is A$22.49 Mil. Therefore, Cleo Diagnostics's FCF Yield % for today is -7.87%.

The historical rank and industry rank for Cleo Diagnostics's FCF Yield % or its related term are showing as below:

ASX:COV' s FCF Yield % Range Over the Past 10 Years
Min: -13.8 Med: 0 Max: 0
Current: -7.87

ASX:COV's FCF Yield % is ranked worse than
61.13% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: -2.63 vs ASX:COV: -7.87

Cleo Diagnostics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Cleo Diagnostics FCF Yield % Historical Data

The historical data trend for Cleo Diagnostics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics FCF Yield % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

FCF Yield %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
FCF Yield %	-	-	-11.22

Competitive Comparison of Cleo Diagnostics's FCF Yield %

For the Medical Devices subindustry, Cleo Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's FCF Yield % falls into.

Cleo Diagnostics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cleo Diagnostics's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1.024	/	0
	=	N/A%

Cleo Diagnostics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.298	*	2	/	23.13
	=	-11.22%

Cleo Diagnostics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Cleo Diagnostics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines